Crossmark

Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient

Crossref DOI link: https://doi.org/10.1186/s40425-019-0818-3

Published Online: 2019-12-02

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pillonel, Vincent

Dunet, Vincent

Hottinger, Andreas F.

Berthod, Gregoire

Schiappacasse, Luis

Peters, Solange

Michielin, Olivier

Aedo-Lopez, Veronica https://orcid.org/0000-0003-0629-4508
License Information

Text and Data Mining valid from 2019-12-01
More Information

Article History

Received: 22 June 2019

Accepted: 12 November 2019

First Online: 2 December 2019

Ethics approval and consent to participate

: Not Applicable.

: The patient provided full consent for participation and publication.

: Solange Peters has received education grants, provided consultation, attended advisory boards, and/or provided lectures for: Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Incyte, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics and Takeda, from whom she has received honoraria (fees to institution). The remaining authors declare that they have no competing interests.